Overview

Phase III Study of 5LGr to Treat Tic Disorder

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effective and safety of 5LGr in pediatric patients with tic disorders.
Phase:
Phase 3
Details
Lead Sponsor:
Tasly Pharmaceuticals, Inc.
Treatments:
Tiapride Hydrochloride